by M.J. Betenbaugh, PhD, N. Arden, and T. Nivitchanyong
Volume 3, Issue 2 (March/April 2004)
Within the biopharmaceutical industry, mammalian cell culture is extensively used to manufacture a various biopharmaceutics uncluding antibodies, interferons, hormones, crythropoietin, clotting factors, immunoadhesins, and vaccines. The market for monoclonal antibodies (MAbs) alone is expected to grow 30% a year and reach sales of nearly $6.5 billion in 2004. The vast majority of these biotherapeutics are secreted glycoproteins obtained from mammalian cell lines such as: Chinese hamster ovary (CHO), human embryonic kidney 293 (HEK-293 or 293). NS0, and baby hamster kidney (BHK). As is the goal with most commercial products, biotechnologists strive to generate these valuable proteins in the highest yields possible in order to utilize mammalian bioreactor facilities efficiently…
Citation:
Betenbaugh MJ, Arden N, Nivitchanyong T. Cell Engineering Blocks Cell Stress and Improves Biotherapeutic Production. BioProcess J, 2004; 3(2): 23-28.